Chemotherapy pro-drug activation by biocatalytic virus-like nanoparticles containing cytochrome P450.
This work shows, for the first time, the encapsulation of a highly relevant protein in the biomedical field into virus-like particles (VLPs). A bacterial CYP variant was effectively encapsulated in VLPs constituted of coat protein from cowpea chlorotic mottle virus (CCMV). The catalytic VLPs are able to transform the chemotherapeutic pro-drug, tamoxifen, and the emerging pro-drug resveratrol. The chemical nature of the products was identified, confirming similar active products than those obtained with human CYP. The enzymatic VLPs remain stable after the catalytic reaction. The potential use of these biocatalytic nanoparticles as targeted CYP carriers for the activation of chemotherapy drugs is discussed.
Institute of Biotechnology, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.
Lorena
L
Sánchez-Sánchez
Center for Nanosciences and Nanotechnology, Universidad Nacional Autónoma de México, Ensenada, Baja California, Mexico.
Rubén D
RD
Cadena-Nava
Institute of Biotechnology, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.
Laura A
LA
Palomares
Institute of Physics, Autonomous University of San Luis, San Luis Potosi, SLP, Mexico.
Jaime
J
Ruiz-Garcia
Department of Biomolecular Nanotechnology, MESA Institute of Nanotechnology, University of Twente, The Netherlands.
Melissa S T
MS
Koay
Department of Biomolecular Nanotechnology, MESA Institute of Nanotechnology, University of Twente, The Netherlands.
Jeroen J M T
JJ
Cornelissen
Institute of Biotechnology, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico; Center for Nanosciences and Nanotechnology, Universidad Nacional Autónoma de México, Ensenada, Baja California, Mexico. Electronic address: rvd@cnyn.unam.mx.
Rafael
R
Vazquez-Duhalt
D065767:Activation, Metabolic; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism; D001410:Bacillus megaterium / Q000235:genetics / Q000378:metabolism; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D055162:Biocatalysis; D017795:Bromovirus / Q000737:chemistry / Q000648:ultrastructure; D036022:Capsid Proteins / Q000737:chemistry; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D006801:Humans; D007700:Kinetics; D053769:Nanocapsules; D053758:Nanoparticles / Q000378:metabolism; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism*; D000077185:Resveratrol; D013267:Stilbenes / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage / Q000378:metabolism; D014771:Virion / Q000378:metabolism
D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D036022:Capsid Proteins; D004337:Drug Carriers; D053769:Nanocapsules; D011355:Prodrugs; D013267:Stilbenes; D013629:Tamoxifen; D003577:Cytochrome P-450 Enzyme System; D000077185:Resveratrol
Bionanotechnology; CYP; Catalytic VLPs; Resveratrol; Tamoxifen